2025Year7July2Day, the National Health Commission announced that according to the "Food Safety Law of the People's Republic of China", after strict safety assessment and expert review, it officially included the Lactobacillus strain of Animal BifidobacteriumBLa80（Bifidobacterium animalis subsp. lactis BLa80）in the "List of Strains of Microorganisms that can be Used in Food for Infants and Young Children". This marks the first time that a domestically developed probiotic strain in Mainland China has successfully entered the list, achieving a historic breakthrough in the core raw materials of infant functional food in China!

Breaking the ice with a breakthrough of zero:BLa80A milestone approval

End the dependence on core raw materials and achieve self-control and self-reliance:For a long time, the strains in China's "List of Microorganisms Available for Use in Infant Food" have been controlled by overseas R&D and introduction.BLa80's successful approval has completely broken this situation, announcing that China has its own independently developed, safe and reliable, and suitable for the most sensitive infant group "Chinese core" probiotic strains, ensuring the supply chain security of key health raw materials.

A strong testament to the national strategy and scientific research capabilities:BLa80 approval is an important achievement of the state's continuous promotion of the "Healthy China" strategy and in-depth implementation of the "Maternal and Child Safety Action Plan". It embodies the state's high emphasis on scientific and technological innovation in the field of infant and child nutrition and health, and is also a strong proof of China's scientific research capabilities in the development, functional evaluation, and industrial application of microbial resources have entered the ranks of the world's leading countries.

Promoting Industrial Upgrade and Leading the Global Track:This breakthrough will greatly boost the innovation confidence and development momentum of China's probiotics industry, driving the upgrading of the complete industry chain from the construction of strain resource libraries, basic research, clinical verification to terminal applications. China's probiotics industry has officially entered a new stage where it has its own intellectual property rights core strains and participates in the global high-end market competition, contributing Chinese wisdom and solutions to the global health of infants and young children.

From the beginning of life: The natural advantages of breast milkBLa80

BLa80One of the core values of the strain lies in its direct isolation from healthy human breast milk collected from pollution-free high-altitude pastoral areas, which also makes it the first animal double-stranded bacteria isolated from breast milk in China to be included in the "List of Strains for Use in Infant Food". This precious source endows it with unparalleled adaptability and functional potential.

Natural affinity, strong colonizing power:As a strain of homologous bacteria that are the early "natives" of the infant intestinal tract,BLa80has a natural affinity and adaptability to the infant intestinal environment, with a higher colonizing efficiency, which can form a barrier of beneficial bacteria群 more quickly and effectively in the infant intestinal tract.

Precise matching of physiological needs of infants and young children:Breast milk-derived strains, through a long history of coevolution, have metabolic characteristics and physiological functions that highly match the digestive absorption and immune development needs of infants and young children.BLa80is applied to simulate and continue the natural shaping effect of breast milk on the intestinal microecology of infants.

The representativeness of local strains:Originating from the local population in China, it means thatBLa80 may be more adapted to the genetic background, dietary structure, and regional environmental characteristics of Chinese infants, providing more targeted tools to address the unique nutritional and health issues of Chinese infants and young children.

Science builds trust:BLa80A solid clinical evidence-based foundation

BLa80 approval was not a fluke, it was built on a rigorous scientific evidence system established by a multi-year, nationwide, multi-center, and thousands of infants participated in a meticulous clinical trial.

Significantly reduce the incidence of infantile diarrhea:Clinical studies have shown that continuous intake of infant formula milk powder containingBLa80can significantly reduce the incidence of acute diarrhea in infants (the effective rate reached51.7%) and the average course of the disease, effectively maintaining intestinal health.

Promote the growth and development of infants and young children and enhance immunity:In 0～36 month-old infants and young children, strict clinical studies have shown thatBLa80can significantly promote the growth of height and weight, significantly reduce the incidence of allergic events, and significantly improve immunoglobulins, proving that BLa80 is safe and effective in promoting the healthy development of infants and young children, regulating immunity, and preventing allergies.

Improving intestinal health indicators:Supplementing BLa80 can observe a reduction in intestinal inflammation and an improvement in barrier function according to relevant indicators, combined with its effective shortening of the course of diarrhea and improvement in defecation characteristics, which strongly supports the BLa80 efficacy in maintaining and improving the intestinal microenvironment and health in infants and young children.

Outstanding safety assurance:All clinical trials are strictly monitored, fully verifying theBLa80high safety and good tolerability in the target infant and toddler population, providing a scientific guarantee of zero additive risks. (Data source: Weikang Probiotic Research Institute)

Bifidobacterium animalis subsp. lactisBLa80的成功 approval and application is a vivid practice of China's self-reliance and self-improvement in the field of science and technology for the health industry, especially in the field of nutrition for mothers and infants. With more "Chinese bacteria" like BLa80 that have independent intellectual property rights and proven efficacy going to market, Chinese infants will gain more nutritionally appropriate health solutions to meet their needs, and China's probiotics industry will also shine more brightly on the global stage. The continuous support of national policies and the powerful driving force of scientific innovation are jointly promoting China's mother and child health industry towards a new era of high-quality development!